Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal.

ABSTRACT:

Background

The World Health Organization recommends two passive immunisation strategies to prevent respiratory syncytial virus (RSV) disease in young infants. Both are being introduced in high-income settings, but their affordability and cost-effectiveness have not been evaluated in many low- and middle-income countries. Preliminary estimates of cost-effectiveness are needed to guide immunisation policy and planning in Nepal.

Methods

We estimated the potential health impact and cost-effectiveness of introducing a maternal vaccine (RSVpreF) or long-acting infant monoclonal antibody (mAb) (nirsevimab) over the period 2025-34 in Nepal. We compared both interventions to the status quo (no intervention) and to each other. Model inputs included health care cost estimates from a re

SUBMITTER: Rave N 

PROVIDER: S-EPMC12615004 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature